Mercado Tratamiento del síndrome de ovario poliquístico (SOP): mapeo competitivo y perspectivas estratégicas 2030

  • Report Code : TIPRE00004072
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Buy Now

La previsión del mercado del tratamiento del síndrome de ovario poliquístico (SOP) ayuda a las partes interesadas en este mercado a delinear sus estrategias de crecimiento. Se prevé que el mercado crecerá de 3460 millones de dólares en 2023 a 5260 millones de dólares en 2031; se estima que registrará una tasa compuesta anual del 5,4 % durante 2023-2031.< /strong>

El aumento de la prevalencia del síndrome de ovario poliquístico a nivel mundial, junto con un aumento significativo del gasto sanitario en el tratamiento del síndrome de ovario poliquístico, son los factores que impulsan el síndrome de ovario poliquístico (SOP) crecimiento del mercado de tratamiento. Por ejemplo, aproximadamente 6 millones de mujeres en Estados Unidos padecen síndrome de ovario poliquístico, un desequilibrio hormonal común. Aumenta el riesgo de varias enfermedades, como cáncer de endometrio, hipertensión, diabetes tipo 2, infertilidad y accidentes cerebrovasculares. Además, la Sociedad Endocrina estima que el diagnóstico y tratamiento del síndrome de ovario poliquístico (SOP), el trastorno hormonal más frecuente que afecta a las mujeres en edad reproductiva, costará 8 mil millones de dólares a nivel nacional en 2020.

El desarrollo de nuevas terapias traerá nuevastendencias en el mercado del tratamiento del síndrome de ovario poliquístico (SOP) durante el período de pronóstico.

< u>Impulsores de crecimiento:

El aumento de la prevalencia del síndrome de ovario poliquístico entre las mujeres a nivel mundial impulsa el crecimiento del mercado de tratamiento del síndrome de ovario poliquístico (SOP)

Análisis Regional:

En términos geográficos, el alcance del síndrome de ovario poliquístico (SOP ) El informe del mercado de tratamiento incluye América del Norte, Europa, Asia Pacífico, Sur y Asia. Centroamérica y Medio Oriente y Asia. África. En 2023, América del Norte tenía la mayor cuota de mercado. La creciente adopción de las últimas tecnologías de dispositivos médicos, la creciente prevalencia del síndrome de ovario poliquístico (SOP) y las crecientes innovaciones de productos por parte de actores clave contribuyen al creciente tamaño del mercado de tratamiento del síndrome de ovario poliquístico (SOP) en América del Norte. Según el Departamento de Salud y Salud de EE. UU. Servicios Humanos, el síndrome de ovario poliquístico es una causa común de infertilidad femenina en los EE. UU., que afecta a entre el 6% y el 12% (~5 millones) de las mujeres estadounidenses en edad reproductiva. Según el estudio "Incidencia, prevalencia y tendencias en el diagnóstico del síndrome de ovario poliquístico", Publicado en julio de 2023 en el American Journal of Obstetrics and Gynecology, la tasa de incidencia de SOP en los EE. UU. es de 42,5 casos por cada 10.000 personas cada año. Además, varias organizaciones en el país ofrecen una evaluación integral, crean conciencia y se centran en la investigación relacionada con el síndrome de ovario poliquístico. Por ejemplo, el Centro de Salud Reproductiva de la UCSF participa activamente en investigaciones para estudiar la causa del síndrome de ovario poliquístico. Así, la alta prevalencia del SOP y la presencia de organizaciones enfocadas en la investigación y concientización favorecen el crecimiento del mercado de tratamiento del síndrome de ovario poliquístico (SOP).

Industria Desarrollos y oportunidades futuras:

Algunos desarrollos estratégicos de los principales actores que operan en el mercado del tratamiento del síndrome de ovario poliquístico (SOP), según la empresa Los comunicados de prensa se enumeran a continuación:

    •En abril de 2023, Celmatix lanzó el programa de medicamentos Novel PCOS. La compañía dio a conocer su programa terapéutico más reciente, dirigido a los receptores de melatonina fuera del sistema nervioso central (SNC). El medicamento terapéutico llenará un vacío crucial en el mercado de terapias efectivas de primera línea para diversas afecciones de salud de las mujeres, comenzando con el síndrome de ovario poliquístico y potencialmente expandiéndose para incluir la endometriosis y los síntomas de la menopausia.•En enero de 2022, Celmatix Inc. anunció un logro histórico en su alianza de cinco años con múltiples objetivos con Evotec. Evotec y Bayer AG impulsaron el hito para avanzar en un programa de medicamentos para el síndrome de ovario poliquístico centrado en un nuevo objetivo farmacológico identificado con Celmatix hacia la identificación de resultados.

Panorama competitivo y claves Empresas:

Sanofi SA, Merck KGaA, Novartis, Mylan, Takeda Pharmaceutical Company Ltd, Abbott, Teva Pharmaceuticals, Salix Pharmaceuticals Inc. , AstraZeneca y Pfizer Inc se encuentran entre las empresas destacadas que se describen en el informe de mercado del tratamiento del síndrome de ovario poliquístico (SOP). Estas empresas se centran en desarrollar nuevas tecnologías, actualizar productos existentes y ampliar su presencia geográfica para satisfacer la creciente demanda de los consumidores en todo el mundo.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which distribution channel segment dominates the polycystic ovarian syndrome (PCOS) treatment market?

The market, by distribution channel, is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest polycystic ovarian syndrome (PCOS) treatment market share in 2023, and it is anticipated to register the highest CAGR during the forecast period.

Which product segment dominates the polycystic ovarian syndrome (PCOS) treatment market?

By product, the market is segmented into clomiphene citrate, metformin, pioglitazone, oral contraceptives, and others. The metformin segment held a larger polycystic ovarian syndrome (PCOS) treatment market share in 2023. Further, the clomiphene citrate segment is anticipated to register a faster CAGR during the forecast period.

What are the growth estimates for the polycystic ovarian syndrome (PCOS) treatment market till 2031?

The polycystic ovarian syndrome (PCOS) treatment market is expected to be valued at US$ 5.26 billion in 2031.

What was the estimated polycystic ovarian syndrome (PCOS) treatment market size in 2023?

The polycystic ovarian syndrome (PCOS) treatment market was valued at US$ 3.46 billion in 2023.

Who are the major players in the polycystic ovarian syndrome (PCOS) treatment market?

The polycystic ovarian syndrome (PCOS) treatment market majorly consists of the players, including Sanofi SA, Merck KGaA, Novartis, Mylan, Takeda Pharmaceutical Company Ltd, Abbott, Teva Pharmaceuticals, Salix Pharmaceuticals Inc, AstraZeneca, and Pfizer Inc

What is polycystic ovarian syndrome (PCOS)?

Polycystic Ovary Syndrome (PCOS) is a hormonal disorder that causes enlarged ovaries with cysts on their outer edges. Some symptoms of PCOS include excess hair growth, acne, missed or irregular menstrual periods, infertility, and weight gain.

What factors drive the polycystic ovarian syndrome (PCOS) treatment market?

Factors such as the increasing prevalence of polycystic ovary syndrome (PCOS) among women globally and increasing government initiatives and support for research in the field of reproductive health propel the polycystic ovarian syndrome (PCOS) treatment market growth. However, the limited availability of FDA-approved medications specifically for PCOS hamper the growth of the market.

The List of Companies - Polycystic Ovarian Syndrome (PCOS) Treatment Market

  1. Sanofi SA
  2. Merck KGaA
  3. Novartis
  4. Mylan
  5. Takeda Pharmaceutical Company Ltd
  6. Abbott
  7. Teva Pharmaceuticals
  8. Salix Pharmaceuticals, Inc
  9. AstraZeneca
  10. Pfizer Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports